These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

813 related articles for article (PubMed ID: 22536382)

  • 21. Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model.
    Cameron MJ; Kelvin AA; Leon AJ; Cameron CM; Ran L; Xu L; Chu YK; Danesh A; Fang Y; Li Q; Anderson A; Couch RC; Paquette SG; Fomukong NG; Kistner O; Lauchart M; Rowe T; Harrod KS; Jonsson CB; Kelvin DJ
    PLoS One; 2012; 7(9):e45842. PubMed ID: 23029269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.
    Hu H; Lu X; Tao L; Bai B; Zhang Z; Chen Y; Zheng F; Chen J; Chen Z; Wang H
    Clin Vaccine Immunol; 2007 Jul; 14(7):894-901. PubMed ID: 17494640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets.
    Darnell ME; Plant EP; Watanabe H; Byrum R; St Claire M; Ward JM; Taylor DR
    J Infect Dis; 2007 Nov; 196(9):1329-38. PubMed ID: 17922397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Animal models and vaccines for SARS-CoV infection.
    Roberts A; Lamirande EW; Vogel L; Jackson JP; Paddock CD; Guarner J; Zaki SR; Sheahan T; Baric R; Subbarao K
    Virus Res; 2008 Apr; 133(1):20-32. PubMed ID: 17499378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe acute respiratory syndrome coronaviruses with mutations in the E protein are attenuated and promising vaccine candidates.
    Regla-Nava JA; Nieto-Torres JL; Jimenez-Guardeño JM; Fernandez-Delgado R; Fett C; Castaño-Rodríguez C; Perlman S; Enjuanes L; DeDiego ML
    J Virol; 2015 Apr; 89(7):3870-87. PubMed ID: 25609816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.
    Ishii K; Hasegawa H; Nagata N; Ami Y; Fukushi S; Taguchi F; Tsunetsugu-Yokota Y
    Microbiol Immunol; 2009 Feb; 53(2):75-82. PubMed ID: 19291090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
    Du L; Zhao G; Lin Y; Sui H; Chan C; Ma S; He Y; Jiang S; Wu C; Yuen KY; Jin DY; Zhou Y; Zheng BJ
    J Immunol; 2008 Jan; 180(2):948-56. PubMed ID: 18178835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV.
    Gai WW; Zhang Y; Zhou DH; Chen YQ; Yang JY; Yan HM
    Virol Sin; 2011 Apr; 26(2):81-94. PubMed ID: 21468931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies.
    Faber M; Lamirande EW; Roberts A; Rice AB; Koprowski H; Dietzschold B; Schnell MJ
    J Gen Virol; 2005 May; 86(Pt 5):1435-1440. PubMed ID: 15831955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus.
    Sheahan T; Whitmore A; Long K; Ferris M; Rockx B; Funkhouser W; Donaldson E; Gralinski L; Collier M; Heise M; Davis N; Johnston R; Baric RS
    J Virol; 2011 Jan; 85(1):217-30. PubMed ID: 20980507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection.
    Du L; Zhao G; Lin Y; Chan C; He Y; Jiang S; Wu C; Jin DY; Yuen KY; Zhou Y; Zheng BJ
    Vaccine; 2008 Mar; 26(13):1644-51. PubMed ID: 18289745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice.
    Tang L; Zhu Q; Qin E; Yu M; Ding Z; Shi H; Cheng X; Wang C; Chang G; Zhu Q; Fang F; Chang H; Li S; Zhang X; Chen X; Yu J; Wang J; Chen Z
    DNA Cell Biol; 2004 Jun; 23(6):391-4. PubMed ID: 15231072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection
    Luan N; Li T; Wang Y; Cao H; Yin X; Lin K; Liu C
    Front Immunol; 2022; 13():882856. PubMed ID: 35464483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice.
    Qu D; Zheng B; Yao X; Guan Y; Yuan ZH; Zhong NS; Lu LW; Xie JP; Wen YM
    Vaccine; 2005 Jan; 23(7):924-31. PubMed ID: 15603894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.
    Bukreyev A; Lamirande EW; Buchholz UJ; Vogel LN; Elkins WR; St Claire M; Murphy BR; Subbarao K; Collins PL
    Lancet; 2004 Jun; 363(9427):2122-7. PubMed ID: 15220033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein.
    Zhi Y; Kobinger GP; Jordan H; Suchma K; Weiss SR; Shen H; Schumer G; Gao G; Boyer JL; Crystal RG; Wilson JM
    Virology; 2005 Apr; 335(1):34-45. PubMed ID: 15823604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease.
    Enjuanes L; Dediego ML; Alvarez E; Deming D; Sheahan T; Baric R
    Virus Res; 2008 Apr; 133(1):45-62. PubMed ID: 17416434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys.
    Zhou J; Wang W; Zhong Q; Hou W; Yang Z; Xiao SY; Zhu R; Tang Z; Wang Y; Xian Q; Tang H; Wen L
    Vaccine; 2005 May; 23(24):3202-9. PubMed ID: 15837221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine design for severe acute respiratory syndrome coronavirus.
    He Y; Jiang S
    Viral Immunol; 2005; 18(2):327-32. PubMed ID: 16035944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies of SARS virus vaccines.
    Zheng BJ; Du LY; Zhao GY; Lin YP; Sui HY; Chan C; Ma S; Guan Y; Yuen KY
    Hong Kong Med J; 2008 Aug; 14 Suppl 4():39-43. PubMed ID: 18708674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.